NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis

International Journal of Antimicrobial Agents

Volumn 29, Issue 6, 2007, Pages 724-727

  Papadopoulou, Maria V ^a   Bloomer, William D ^a   McNeil, Michael R ^b  

^a Evanston Northwestern Healthcare ^*  (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Dormancy; Mycobacterium tuberculosis; Nitroimidazole prodrugs; NLCQ 1; NLCQ 2

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; 4 [4 (2 NITRO 1 IMIDAZOLYL)BUTYLAMINO] 7 CHLOROQUINOLINE; ANTINEOPLASTIC AGENT; CAPREOMYCIN; CLARITHROMYCIN; DNA; ISONIAZID; MINOCYCLINE; NITROIMIDAZOLE; PRODRUG; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; IC 50; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; VERO CELL;

ANIMALS; ANTITUBERCULAR AGENTS; CERCOPITHECUS AETHIOPS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; PRODRUGS; QUINOLINES; TIME FACTORS; VERO CELLS;

EID: 34248144307     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.01.015     Document Type: Article

References (19)

1. Wayne L.G. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 13 (1994) 908-914
2. Wayne L.G., and Hayes L.G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64 (1996) 2062-2069
3. Dick T. Dormant tubercle bacilli: the key to more effective TB chemotherapy?. J Antimicrob Chemother 47 (2001) 117-118
4. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 43 (1999) 1533-1541
5. Murugasu-Oei B., and Dick T. Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J Antimicrob Chemother 46 (2000) 917-919
6. Brooks J.V., Furney S.K., and Orme I.M. Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother 43 (1999) 1285-1288
7. Stover C.K., Warrener P., Vandevanter D.R., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405 (2000) 962-966
8. Lenaerts A.J., Gruppo V., Marietta K.S., et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49 (2005) 2294-2301
9. Manjunatha U.H., Boshoff H., Dowd C.S., et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 103 (2006) 431-436
10. Papadopoulou M.V., Ji M., Rao M.K., and Bloomer W.D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 12 (2000) 185-192
11. Papadopoulou M.V., Ji M., Rao M.K., and Bloomer W.D. Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol Res 14 (2003) 21-29
12. Collins L., and Franzblau S.G. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41 (1997) 1004-1009
13. Jayaprakash S., Iso Y., Wan B., Franzblau S.G., and Kozikowski A.P. Design, synthesis and SAR studies of mefloquine-based ligands as potential antituberculosis agents. Chem Med Chem 1 (2006) 593-597
14. Papadopoulou M.V., and Bloomer W.D. Exploiting hypoxia in solid tumors with DNA-targeted bioreductive drugs. Drugs Future 29 (2004) 807-819
15. Papadopoulou M.V., and Bloomer W.D. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 9 (2003) 5714-5720
16. McNeil M., Daffe M., and Brennan P.J. Evidence for the nature of the link between the arabinogalactan and peptidoglycan components of mycobacterial cell walls. J Biol Chem 265 (1990) 18200-18206
17. Ma Y., Stern R.J., Scherman M.S., et al. Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob Agents Chemother 45 (2001) 1407-1416
18. Reid J.M., Squillace D.P., and Ames M.M. Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice. Cancer Chemother Pharmacol 51 (2003) 483-487
19. Weber I., Fritz C., Ruttkowski S., Kreft A., and Bange F.C. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol Microbiol 35 (2000) 1017-1025